Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

This study has been completed.

Study NCT00006488 Information provided by National Center for Research Resources (NCRR)

First Received: November 8, 2000 Last Updated: June 23, 2005 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given